Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors

CONCLUSIONS: Mitochondrial abnormalities are characteristic histopathological features, and impaired renal function and HBeAg positivity are risk factors for TIM. Telbivudine-induced mitochondrial dysfunction and immune activation related to mitochondrial damage and HBeAg serostatus changes may underlie TIM. Constant clinical surveillance of myopathy during telbivudine treatment is needed due to the significant latency of its development. Dose adjustment for impaired renal function does not eliminate the risk of TIM occurrence.PMID:36606646 | DOI:10.3988/jcn.2023.19.1.52

Source: Journal of Clinical Neurology - January 6, 2023 Category: Neurology Authors: Min-Yu Lan Hui-Chen Lin Tsung-Hui Hu Shu-Fang Chen Chien-Hung Chen Yung-Yee Chang King-Wah Chiu Tsu-Kung Lin Shun-Sheng Chen Source Type: research